TUESDAY, SEPTEMBER 27, 2016

GenScript aids Novavax's H7N9 vaccine development

GenScript announced on Monday that it has aided Novavax, Inc., in the development of a H7N9 avian influenza vaccine candidate by providing Rush Gene Services.

GenScript's Rush Gene Service is capable of synthesizing gene sequences in as little as four days. It would normally take up to two weeks or even more to assemble constructs used to produce the H7N9 vaccine. The service cuts down on this time with its one-step platform, which utilizes a combination of gene optimization, rush gene synthesis and custom cloning.

"Our mission is to save lives by helping scientists accelerate their research. In this case, our Rush Gene Services are the perfect example of our commitment to our mission," GenScript CEO Frank Zhang, said. "The progress made by scientists at Novavax on its H7N9 vaccine candidate in such a short time is the reason why we are dedicated to providing high-quality services on a daily basis."

Construction of the genes containing key vaccine proteins took place in six days. This allowed Novavax to develop a vaccine candidate in only 28 days and within six weeks of the release of initial H7N9 infection reports on April 1.